| Title |
Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, February 2018
|
| DOI | 10.1007/s10549-018-4684-3 |
| Pubmed ID | |
| Authors |
Nicholas B. Figura, Wendy Long, Michael Yu, Timothy J. Robinson, Sepideh Mokhtari, Arnold B. Etame, Nam D. Tran, Roberto Diaz, Hatem Soliman, Heather S. Han, Solmaz Sahebjam, Peter A. Forsyth, Kamran A. Ahmed |
| Abstract |
Leptomeningeal disease is a rare and devastating presentation of advanced stage metastatic breast cancer with historically poor overall survival. We assessed the safety and feasibility of intrathecal (IT) trastuzumab in HER2+ leptomeningeal disease. A total of 13 patients were treated at our institution with IT trastuzumab beginning November 2012 and followed until November 2017. Outcomes including craniospinal progression as well as overall survival (OS) following initiation of IT trastuzumab were assessed from review of the clinical chart and radiologic examinations. The median age of patients was 48 (range 29-75). Median time from breast cancer diagnosis to development of brain metastases was 87.7 months with a median of 4.6 months from brain metastases diagnosis to the development of leptomeningeal disease. Previous whole brain radiotherapy was received by the majority of patients (92%) and prior surgery for brain metastases was performed in 23%. Median duration of IT trastuzumab treatment was 6.4 months. Median time from IT trastuzumab start to craniospinal progression was 5.7 months with 6- and 12-month Kaplan-Meier rates of 41 and 21%, respectively. Sustained responses > 6 months were achieved in 4 patients. Median survival from the start of IT trastuzumab was 10.6 months with 6- and 12-month OS rates of 68 and 47%, respectively. IT trastuzumab was well tolerated with one patient developing ventriculitis, which resolved with IV antibiotics. IT trastuzumab was well tolerated with prolongation of OS over historical controls. IT trastuzumab should be considered for management of HER2+ leptomeningeal disease patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 20% |
| Other | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Bachelor | 4 | 8% |
| Student > Postgraduate | 4 | 8% |
| Other | 9 | 18% |
| Unknown | 11 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 12% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Immunology and Microbiology | 1 | 2% |
| Chemical Engineering | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 14 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2018.
All research outputs
#15,683,389
of 23,305,591 outputs
Outputs from Breast Cancer Research and Treatment
#3,343
of 4,707 outputs
Outputs of similar age
#271,177
of 441,628 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#47
of 76 outputs
Altmetric has tracked 23,305,591 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,707 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,628 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.